Loading clinical trials...
Loading clinical trials...
Assessment of the Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin. Multicentric, Double-Blinded, Randomized Study. ANRS HC18 Paropeg
Conditions
Interventions
Paroxetine
Locations
1
France
Service d'Hépato-gastroentérologie CHU de Nancy
Vandœuvre-lès-Nancy, France
Start Date
October 1, 2005
Completion Date
February 1, 2009
Last Updated
May 13, 2009
NCT00199719
NCT06922643
NCT03612973
NCT01866930
NCT05895448
NCT02219490
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions